Home Protein Tyrosine Kinase Insulin Receptor

Insulin Receptor

Other Protein Tyrosine Kinase Related Inhibitors

VEGFR EGFR c-Met PDGFR CSF-1R IGF-1R c-Kit ALK Tie-2 HER2
Cat.No. Product Name Information Product Use Citations Product Validations
S6922 S961 S961 is a biosynthetic insulin receptor antagonist that inhibits cellular proliferation and colony formation in breast tumour cells.
Front Immunol, 2025, 16:1620571
Hepatol Commun, 2025, 9(9)e0793
J Neuroendocrinol, 2024, e13446.
S1091 Linsitinib (OSI-906) Linsitinib (OSI-906) is a selective inhibitor of IGF-1R with IC50 of 35 nM in cell-free assays. It is modestly potent to InsR with IC50 of 75 nM, and shows no activity towards Abl, ALK, BTK, EGFR, FGFR1/2, PKA etc. Phase 3.
Cancer Biology & Medicine, June 9, 2021, 229-252
Molecular Cancer Therapeutics, January 3, 2023, 63-74
Theranostics, January 1, 2022, 1097-1116
Verified customer review of Linsitinib (OSI-906)
S1124 BMS-754807 BMS-754807 is a potent and reversible inhibitor of IGF-1R/InsR with IC50 of 1.8 nM/1.7 nM in cell-free assays, less potent to Met (c-Met), Aurora A/B, TrkA/B and Ron, and shows little activity to Flt3, Lck, MK2, PKA, PKC etc. Phase 2.
Molecular Cancer Research, September 02 2022, 1405-1419
Acta Pharmacologica Sinica, July 17 2019, 270-277
Cell Reports, August 26 2025, 116149
Verified customer review of BMS-754807